sulotroban

thromboxane receptor antagonist

Also Known As:

4-(2-(benzenesulfonamido)ethyl)phenoxyacetic acid; BM 13,177; BM 13.177; BM 13177; BM-13177; SK&F 95587; SK&F-95587; SKF 95587; SKF-95587; Acetic acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)-

Networked: 31 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - sulotroban: 31
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - sulotroban: 31

Experts

1.	Fu, Liang-Wu: 1 article (12/2008)
2.	Longhurst, John C: 1 article (12/2008)
3.	Phan, Andrew: 1 article (12/2008)

Related Diseases

1.	Sudden Death 01/01/1984 - "Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death." 01/01/1988 - "Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats." 01/01/1988 - "The purpose of this study was to evaluate the pharmacology and pharmacodynamics of the thromboxane receptor antagonists, BM 13.177 and BM 13.505, for prevention of U 46619-induced sudden death in anesthetized male Sprague-Dawley rats. " 01/01/1988 - "These data demonstrate that BM 13.177 and BM 13.505 prevented sudden death produced by the injection of U 46619. " 01/01/1984 - "In mice, BM 13.177 prevented in a dose-dependent fashion the sudden death and the symptoms of respiratory depression and shock induced by i.v. injections of U 46619 or arachidonic acid. "
2.	Thrombosis (Thrombus) 08/15/1984 - "The protective effect of BM 13.177 may, therefore, be due to the TXA2-antagonizing effect of BM 13.177, which has been conclusively demonstrated in human platelets (PATSCHEKE and STEGMEIER, Thrombosis Res., 33, 277-288 (1984). " 01/01/1989 - "Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis." 09/15/1988 - "The stable PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban were investigated for possible cooperative effects on platelet function and experimental thrombus formation in guinea pigs and rats. " 03/01/1988 - "It is concluded that, in this porcine model of coronary artery thrombosis, the thromboxane antagonist BM 13.177 effectively suppressed formation of occlusive thrombi whereas acetylsalicylate was ineffective at a dose that lowered arterial thromboxane levels." 03/01/1988 - "The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig."
3.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/2008 - "BM 13,177 (30 mg/kg iv), a selective TP receptor antagonist, eliminated the reflex responses to U-46619 and significantly attenuated the excitatory responses during brief (5 min) regional myocardial ischemia. " 12/01/1987 - "Resting myocardial ischemia after intravenous infusion of BM 13.177 (sulotroban), a thromboxane receptor antagonist."
4.	Cardiac Arrhythmias (Arrythmia) 01/01/1988 - "TX receptor antagonizing substances such as BM 13177 and specific PAF antagonists for example BN 52021 and WEB 2086, completely inhibited the PAF induced cardiac arrhythmias. " 01/01/1988 - "The TX receptor antagonist BM 13177, the lipoxygenase inhibitor esculetin were effective in ouabain and aconitine induced arrhythmias while the PGI2 formation stimulating substance nafazatrom was only effective in aconitine induced arrhythmia. "
5.	Stomach Ulcer (Gastric Ulcer) 09/01/1987 - "Hence, in the present study, the effects of pirenzepine, cimetidine, disodium cromoglycate, OKY-046 (a thromboxane A2 synthesis inhibitor), BM 13.177 (a thromboxane A2 receptor antagonist), FPL 55712 (a leukotriene C4 antagonist) and a synthetic trimethylprostanoid, Ro 22-6923 have been studied on the gastric ulcers produced by indomethacin and its combination with morphine in rats. "

Related Drugs and Biologics

1.	Thromboxane Receptors (Thromboxane Receptor)
2.	sulotroban
3.	Thromboxane A2 (A2, Thromboxane)
4.	daltroban
5.	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
6.	nafazatrom
7.	Lipoxygenase Inhibitors
8.	Tissue Plasminogen Activator (Alteplase)
9.	Ouabain (G Strophanthin)
10.	Aconitine

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Therapeutics
3.	Injections